Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Double-blind, RandomizEd, Prospective, Placebo Controlled STudy of NanO2TM Combined With Radiation and Temozolomide in Patients With Newly-diagnosed Glioblastoma multiformE: RESTORE

NCT03862430 is registered in ClinicalTrials.gov with NuvOx LLC as lead sponsor.

NCT NCT03862430
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03862430 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Double-blind, RandomizEd, Prospective, Placebo Controlled STudy of NanO2TM Combined With Radiation and Temozolomide in Patients With Newly-diagnosed Glioblastoma multiformE: RESTORE
Lead sponsor
NuvOx LLC
Phase
Phase 2
Overall status
Active, not recruiting
Start date
March 31, 2023
Completion date
September 30, 2027
Enrollment
87 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma multiforme